AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop next-generation cancer biotherapeutics. The partnership will focus on creating multispecific biologics targeting various oncology indications and aims to address the issue of cancer cell resistance to existing immunotherapies by employing EvolveImmune’s proprietary T-cell engager EVOLVE platform. The gold standard of business intelligence.
The platform, with its cluster of differentiation 2 strategies, is designed to deliver potent, selective, and integrated T-cell costimulation, enhancing the tumour-killing capacity of T cells. The strategy is to bypass low tumour immunogenicity, activate adaptive immunity conditionally, and minimise T-cell dysfunction in both solid and haematologic malignancies. Under the agreement terms, EvolveImmune is eligible to obtain an aggregate of $65m in upfront fees from AbbVie along with equity investment.
Additionally, EvolveImmune will receive option fees and milestone payments of up to $1.4bn, and tiered royalties on future net sales. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form AbbVie dis.
